Sanara MedTech CEO granted 25,430 restricted shares

Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Yon Seth D reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. reported that Chief Executive Officer Yon Seth D received a grant of 25,430 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, he directly holds 113,398 common shares.

The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, provided he remains employed by the company through each vesting date. This represents compensation rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 25,430 shares

Grant/Award 1 txn

Insider Yon Seth D

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,430	$0.00	$0.00

Holdings After Transaction: Common Stock — 113,398 shares (Direct)

Footnotes (1)

1. F1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sanara MedTech (SMTI) report for CEO Yon Seth D?

Sanara MedTech reported that CEO Yon Seth D received 25,430 restricted shares of common stock as a compensation grant. The shares were issued at no cash cost to him under the 2024 Omnibus Long-Term Incentive Plan, increasing his direct holdings to 113,398 shares.

How many Sanara MedTech (SMTI) shares does the CEO hold after this Form 4 grant?

After the restricted stock grant, CEO Yon Seth D directly holds 113,398 shares of Sanara MedTech common stock. This total includes the newly awarded 25,430 restricted shares, which are subject to multi-year vesting conditions tied to his continued employment with the company.

What are the vesting terms of the 25,430 restricted shares granted by Sanara MedTech (SMTI)?

The 25,430 restricted shares vest in three equal installments on March 22, 2027, 2028 and 2029. Each one-third tranche vests only if CEO Yon Seth D remains employed by Sanara MedTech through the applicable vesting date, aligning the award with long-term service.

Was the Sanara MedTech (SMTI) CEO’s Form 4 transaction an open-market stock purchase or sale?

The transaction was not an open-market trade; it was a grant of restricted stock. CEO Yon Seth D acquired 25,430 shares at a stated price of $0.0000 per share as a compensation award, rather than buying or selling shares on the open market.

Under which plan did Sanara MedTech (SMTI) grant restricted stock to its CEO?

The restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan authorizes equity-based awards such as restricted stock, and the CEO’s 25,430-share grant is structured to vest over three years based on continued employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yon Seth D

(Last) (First) (Middle)

1200 SUMMIT AVE

SUITE 414

(Street)

FORT WORTH TEXAS 76102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		A		25,430(1)	D	$0(1)	113,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on March 22, 2027, 2028 and 2029, respectively, provided that the reporting person is employed by the Issuer through each such date.

	/s/ Seth D. Yon	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)